Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Functional treatments in multiple sclerosis.
Courtney AM, Castro-Borrero W, Davis SL, Frohman TC, Frohman EM. Courtney AM, et al. Curr Opin Neurol. 2011 Jun;24(3):250-4. doi: 10.1097/WCO.0b013e328346055a. Curr Opin Neurol. 2011. PMID: 21455067 Review.
Current and emerging therapies in multiple sclerosis: a systematic review.
Castro-Borrero W, Graves D, Frohman TC, Flores AB, Hardeman P, Logan D, Orchard M, Greenberg B, Frohman EM. Castro-Borrero W, et al. Ther Adv Neurol Disord. 2012 Jul;5(4):205-20. doi: 10.1177/1756285612450936. Ther Adv Neurol Disord. 2012. PMID: 22783370 Free PMC article.
Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study.
Gold R, Radue EW, Giovannoni G, Selmaj K, Havrdova EK, Montalban X, Stefoski D, Sprenger T, Robinson RR, Fam S, Smith J, Chalkias S, Giannattasio G, Lima G, Castro-Borrero W. Gold R, et al. Among authors: castro borrero w. J Neurol. 2020 Oct;267(10):2851-2864. doi: 10.1007/s00415-020-09835-y. Epub 2020 May 25. J Neurol. 2020. PMID: 32451615 Free PMC article. Clinical Trial.
Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination.
Kappos L, Cohan S, Arnold DL, Robinson RR, Holman J, Fam S, Parks B, Xiao S, Castro-Borrero W. Kappos L, et al. Among authors: castro borrero w. Ther Adv Neurol Disord. 2021 Feb 26;14:1756286420987941. doi: 10.1177/1756286420987941. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 33737954 Free PMC article.
Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.
Krueger JG, Kircik L, Hougeir F, Friedman A, You X, Lucas N, Greenberg SJ, Sweetser M, Castro-Borrero W, McCroskery P, Elkins J. Krueger JG, et al. Among authors: castro borrero w. Adv Ther. 2016 Jul;33(7):1231-45. doi: 10.1007/s12325-016-0353-2. Epub 2016 Jun 1. Adv Ther. 2016. PMID: 27251051 Free PMC article. Clinical Trial.
13 results